RCKT: FDA clears pivotal Danon gene therapy trial; robust pipeline and cash runway support growth
The company is advancing three cardiovascular gene therapy programs, with the Danon disease trial cleared by the FDA to proceed at a recalibrated dose and revised safety regimen. Strong cash reserves support ongoing trials, and a comprehensive update is planned for October 6th. Early data in PKP2 a…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.